-
1.发明申请MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS 审中-公开用于治疗感冒的改良的2'和3'-核苷酸产物公开(公告)号：US20130330297A1
公开(公告)日：2013-12-12
申请号：US13958463
申请日：2013-08-02
申请人： Idenix Pharmaceuticals, Inc. , L'Universite Montpellier II (UMII) , Centre National De La Recherche Scientifique (CNRS) , Universita degli Studi di Cagliari
IPC分类号： A61K38/21 , A61K31/7068 , A61K31/7072 , A61K31/708 , A61K31/7076
CPC分类号： C07H19/16 , A61K9/20 , A61K9/48 , A61K31/675 , A61K31/7056 , A61K31/7068 , A61K31/7072 , A61K31/7076 , A61K31/708 , A61K38/21 , A61K38/212 , A61K45/06 , A61K47/60 , C07H19/00 , C07H19/04 , C07H19/048 , C07H19/056 , C07H19/06 , C07H19/22 , A61K2300/00
摘要： 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branchednucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.
摘要翻译： 描述了1'，2'，3'或4'-支链核苷的2'和/或3'前药及其药学上可接受的盐和衍生物。 这些前药可用于预防和治疗黄病毒科感染，包括HCV感染和其他相关病症。 描述本发明前药的化合物和组合物。 还提供了包括施用有效量的本发明前药或其药学上可接受的盐或衍生物的方法和用途。 这些药物可以任选地与另外的抗病毒剂组合或改变来施用，以预防或治疗黄病毒科感染和其他相关病症。
-
2.发明申请MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS 审中-公开用于治疗感冒的改良的2'和3'-核苷酸产物公开(公告)号：US20140113880A1
公开(公告)日：2014-04-24
申请号：US14146520
申请日：2014-01-02
申请人： Idenix Pharmaceuticals, Inc. , L'Universite Montpellier II , Centre National de la Recherche Scientiflque , Universita degli Studi di Cagliari
IPC分类号： C07H19/16
CPC分类号： C07H19/16 , A61K9/20 , A61K9/48 , A61K31/675 , A61K31/7056 , A61K31/7068 , A61K31/7072 , A61K31/7076 , A61K31/708 , A61K38/21 , A61K38/212 , A61K45/06 , A61K47/60 , C07H19/00 , C07H19/04 , C07H19/048 , C07H19/056 , C07H19/06 , C07H19/22 , A61K2300/00
摘要： 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.
摘要翻译： 描述了1'，2'，3'或4'-支化核苷的2'和/或3'前药及其药学上可接受的盐和衍生物。 这些前药可用于预防和治疗黄病毒科感染，包括HCV感染和其他相关病症。 描述本发明前药的化合物和组合物。 还提供了包括施用有效量的本发明前药或其药学上可接受的盐或衍生物的方法和用途。 这些药物可以任选地与另外的抗病毒剂组合或改变来施用，以预防或治疗黄病毒科感染和其他相关病症。
-
公开(公告)号：US20210024565A1
公开(公告)日：2021-01-28
申请号：US17061409
申请日：2020-10-01
申请人： Idenix Pharmaceuticals LLC , Universita degli Studi di Cagliari , Centre National De La Recherche Scientifique , Universite de Montpellier
IPC分类号： C07H19/16 , A61K47/60 , A61K31/675 , A61K31/7072 , A61K31/7076 , A61K38/21 , A61K45/06 , C07H19/00 , C07H19/04 , C07H19/048 , C07H19/22 , A61K31/7068 , A61K31/708 , C07H19/056 , C07H19/06 , A61K31/7056 , A61K9/20 , A61K9/48
摘要： 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.
-
公开(公告)号：US20180237467A1
公开(公告)日：2018-08-23
申请号：US15890990
申请日：2018-02-07
申请人： Idenix Pharmaceuticals LLC , Universita degli Studi di Cagliari , Centre National De La Recherche Scientifique , Universite de Montpellier
IPC分类号： C07H19/16 , A61K31/7056 , A61K45/06 , C07H19/06 , C07H19/056 , A61K38/21 , A61K31/708 , A61K31/7068 , A61K47/60 , A61K9/48 , A61K9/20 , A61K31/675 , A61K31/7072 , A61K31/7076 , C07H19/22 , C07H19/048 , C07H19/04 , C07H19/00
CPC分类号： C07H19/16 , A61K9/20 , A61K9/48 , A61K31/675 , A61K31/7056 , A61K31/7068 , A61K31/7072 , A61K31/7076 , A61K31/708 , A61K38/21 , A61K38/212 , A61K45/06 , A61K47/60 , C07H19/00 , C07H19/04 , C07H19/048 , C07H19/056 , C07H19/06 , C07H19/22 , A61K2300/00
摘要： 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branchednucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.
-
5.发明授权Compounds and pharmaceutical compositions for the treatment of viral infections 有权用于治疗病毒感染的化合物和药物组合物公开(公告)号：US09249173B2
公开(公告)日：2016-02-02
申请号：US14197078
申请日：2014-03-04
申请人： Idenix Pharmaceuticals, Inc. , Centre National de la Recherche Scientifique , Universite Montpellier II
发明人： Jean-Pierre Sommadossi , Gilles Gosselin , Claire Pierra , Christian Perigaud , Suzanne Peyrottes
IPC分类号： A61K31/70 , C07H17/02 , C07F9/6558 , C07F9/6561 , C07H19/00 , A61K31/675 , A61K31/7056 , A61K31/7064 , A61K31/7068 , A61K31/7072 , A61K31/7076 , A61K31/708
CPC分类号： C07H17/02 , A61K31/675 , A61K31/7056 , A61K31/7064 , A61K31/7068 , A61K31/7072 , A61K31/7076 , A61K31/708 , C07F9/65586 , C07F9/65616 , C07H19/00
摘要： Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and/or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.
摘要翻译： 本文提供了用于治疗肝脏疾病（包括HCV和/或HBV感染）的化合物，组合物和方法。 具体地，公开了核苷衍生物的化合物和组合物，其可以单独施用或与其它抗病毒剂组合施用。
-
6.发明授权Purine nucleoside analogues for treating flaviviridae including hepatitis C 有权嘌呤核苷类似物用于治疗黄病毒科，包括丙型肝炎公开(公告)号：US09186369B2
公开(公告)日：2015-11-17
申请号：US14269003
申请日：2014-05-02
申请人： Idenix Pharmaceuticals, Inc. , The Centre National de la Recherche Scientifique , L'Universite Montpellier II
发明人： Richard Storer , Gilles Gosselin , David Dukhan , Frederic Leroy
IPC分类号： C07H19/23 , C07D487/04 , C07D405/04 , C07D409/04 , A61K31/7052 , A61K31/5025 , A61K31/53 , A61P31/14 , A61K31/706 , A61K31/00 , C07H19/044 , C07H19/052 , C07H19/056 , A61K45/06 , C07H19/04
CPC分类号： A61K31/706 , A61K31/00 , A61K45/06 , C07H19/04 , C07H19/044 , C07H19/052 , C07H19/056 , C07H19/23
摘要： This invention is directed to a method for treating a host, especially a human, infected with hepatitis C, flavivirus and/or pestivirus, comprising administering to that host an effective amount of an anti-HCV biologically active pentofuranonucleoside where the pentofuranonucleoside base is an optionally substituted 2-azapurine. The optionally substituted pentofuranonucleoside, or a salt or prodrug thereof, may be administered alone or in combination with one or more optionally substituted pentofuranonucleosides or other anti-viral agents.
摘要翻译： 本发明涉及用于治疗感染丙型肝炎，黄病毒和/或瘟病毒的宿主，特别是人的方法，包括向该宿主施用有效量的抗HCV生物活性戊呋喃核苷，其中戊呋喃核苷碱基是任选的 取代的2-氮杂嘌呤。 任选取代的五氟鸟苷或其盐或前药可以单独施用或与一种或多种任选取代的五氟鸟苷或其它抗病毒剂组合施用。
-
公开(公告)号：US09309275B2
公开(公告)日：2016-04-12
申请号：US14195388
申请日：2014-03-03
申请人： Idenix Pharmaceuticals, Inc. , Centre National De La Recherche Scientifique , Universite Montpellier 2 Sciences Et Techniques
发明人： Alistair James Stewart , Adel M. Moussa , Benjamin Alexander Mayes , Francois-Rene Alexandre , Dominique Surleraux , Christophe Claude Parsy , Claire Pierra , David Dukhan , Gilles Gosselin
IPC分类号： C07H19/044 , C07H19/06 , C07H19/10 , C07H19/14 , C07H19/16 , C07H19/20 , C07H19/207 , A61K31/708 , A61K31/7068 , A61K31/7076 , A61K31/7072 , A61K45/06 , A61K31/40 , A61K31/497 , A61K31/7056 , A61K38/21
CPC分类号： C07H19/207 , A61K31/40 , A61K31/497 , A61K31/7056 , A61K31/7068 , A61K31/7072 , A61K31/7076 , A61K31/708 , A61K38/212 , A61K45/06 , C07H19/06 , C07H19/10 , C07H19/16 , C07H19/20 , A61K2300/00
摘要： Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3′-deoxy nucleoside compounds according to Formula 3001a or 3001b: or a pharmaceutically acceptable salts, solvates, stereoisomeric forms, tautomeric forms, or polymorphic forms thereof, wherein PD, Base1 and Base2 are as provided herein.
摘要翻译： 本文提供了用于治疗黄病毒科感染（包括HCV感染）的化合物，组合物和方法。 在某些实施方案中，公开了核苷衍生物的化合物和组合物，其可以单独施用或与其它抗病毒剂组合施用。 在某些实施方案中，化合物是根据式3001a或3001b的3'-脱氧核苷化合物：或其药学上可接受的盐，溶剂合物，立体异构形式，互变异构形式或其多晶型，其中PD，碱基和碱基2如本文所提供。
-
公开(公告)号：US09296778B2
公开(公告)日：2016-03-29
申请号：US13899487
申请日：2013-05-21
申请人： Idenix Pharmaceuticals, Inc. , Centre National De La Recherche Scientifique , Universite Montpellier 2 Sciences Et Techniques
发明人： Christophe Claude Parsy , Francois-Rene Alexandre , Cyril B. Dousson , David Dukhan , Gilles Gosselin , Houcine Rahali , Dominique Surleraux
IPC分类号： A61K31/7068 , A61K31/7076 , A61K45/06 , C07H19/10 , C07H19/20 , C07H19/213 , C07H19/11
CPC分类号： C07H19/20 , A61K31/7068 , A61K31/7076 , A61K45/06 , C07H19/10 , C07H19/11 , C07H19/213
摘要： Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.
摘要翻译： 本文提供了用于治疗黄病毒科感染（包括HCV感染）的化合物，组合物和方法。 在某些实施方案中，公开了核苷衍生物的化合物和组合物，其可以单独施用或与其它抗病毒剂组合施用。
-
公开(公告)号：US09211300B2
公开(公告)日：2015-12-15
申请号：US14109463
申请日：2013-12-17
申请人： IDENIX PHARMACEUTICALS, INC. , Centre National De La Recherche Scientifique , Université Montpellier 2 Sciences et Techniques
IPC分类号： C07H19/00 , A61K31/70 , C07H19/10 , C07H19/20 , C07H19/213 , A61K31/708 , A61K31/7072 , A61K45/06 , C07H17/02 , C07H19/06 , C07H19/16 , A61K38/21 , A61K31/403 , A61K31/497 , A61K31/7056
CPC分类号： A61K31/708 , A61K31/403 , A61K31/497 , A61K31/7056 , A61K31/7072 , A61K38/21 , A61K38/212 , A61K45/06 , C07H17/02 , C07H19/06 , C07H19/10 , C07H19/16 , C07H19/20 , C07H19/213 , A61K2300/00
摘要： Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are according to Formula 1501: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein B, PD, RA, RB, RC, L, M and Z are as described herein.
摘要翻译： 本文提供了用于治疗黄病毒科感染（包括HCV感染）的化合物，组合物和方法。 在某些实施方案中，公开了核苷衍生物的化合物和组合物，其可以单独施用或与其它抗病毒剂组合施用。 在某些实施方案中，化合物根据式1501：或其药学上可接受的盐，溶剂化物，立体异构形式，互变异构形式或多晶型，其中B，PD，RA，RB，RC，L，M和Z如本文所述 。
-
10.发明申请BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B 有权用于治疗乙型肝炎的BETA-L-2'-DEOXY-NUCLEOSIDES公开(公告)号：US20130324491A1
公开(公告)日：2013-12-05
申请号：US13849243
申请日：2013-03-22
申请人： Idenix Pharmaceuticals, Inc. , L'Universite Montpellier II , Centre National de la Recherche Scientifique
CPC分类号： C07H19/16 , A61K31/70 , A61K31/7068 , A61K31/7072 , A61K31/7076 , A61K31/708 , C07H19/06 , A61K2300/00
摘要： This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-β-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2′-deoxy-β-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.
摘要翻译： 本发明涉及一种用于治疗感染乙型肝炎的宿主的方法，其包括施用有效量的抗HBV生物活性2'-脱氧-β-L-赤 - 戊呋喃核苷或其药学上可接受的盐或前药，其中 2'-脱氧-β-L-赤 - 戊呋喃核苷具有下式：其中R选自H，直链，支链或环状烷基，CO-烷基，CO-芳基，CO-烷氧基烷基，CO-芳氧基烷基 烷基磺酰基，芳基磺酰基，芳烷基磺酰基，氨基酸残基，单，二或三磷酸酯，或磷酸酯衍生物; 并且BASE是嘌呤或嘧啶碱基，其可任选被取代。 2'-脱氧-β-L-赤 - 戊呋喃核苷或其药学上可接受的盐或前药可以单独或与其它2'-脱氧-β-L-赤 - 戊呋喃核苷组合或与另一种抗 - 乙型肝炎药。
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.052 秒)
